Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
In this study the investigators are going to evaluate the efficacy pentoxifyline in HTLV-1
patients with neurological diseases: HAM/TSP or neurogenic bladder. In some laboratory
experiments the investigators observed that this drug had the capacity to reduce the immune
response in HTLV-1 infected cells. Since the exacerbated immune response is know to cause
neurological disease in patients with HTLV-1 the investigators hope that pentoxifyline can
alleviate symptoms and delay the progress of HAM/TSP in patients.